PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2015 | 5 | 2 | A62-66
Article title

Should a diagnosis of cancer impact the anticoagulant therapy in patients with recurrent thromboembolic disease?

Content
Title variants
Languages of publication
EN
Abstracts
EN
Venous thromboembolism often coexists with cancer, deteriorating patient prognosis. The diagnosis of cancer in patients who suffer from venous thromboembolism may lead to changes in the anticoagulant therapy administered. We present a case report involving a 72-year-old patient with recurrent venous thromboembolism and chronic thromboembolic pulmonary hypertension in whom the diagnosis of colorectal cancer resulted in the need for modification of the anticoagulant therapy. Oral anticoagulant was replaced with low molecular weight heparin and an inferior vena cava filter was implanted due to active bleeding from the anus, high perioperative risk of bleeding, which caused the need for a temporary interruption of anticoagulant therapy.
Discipline
Publisher

Journal
Year
Volume
5
Issue
2
Pages
A62-66
Physical description
Contributors
  • Department of Pulmonary Circulation and Thromboembolic Diseases, Centre of Postgraduate Medical Education, European Health Centre, Otwock, Poland, maria.wieteska@ecz-otwock.pl
  • Department of Pulmonary Circulation and Thromboembolic Diseases, Centre of Postgraduate Medical Education, European Health Centre, Otwock, Poland
  • Department of Pulmonary Circulation and Thromboembolic Diseases, Centre of Postgraduate Medical Education, European Health Centre, Otwock, Poland
author
  • Department of Pulmonary Circulation and Thromboembolic Diseases, Centre of Postgraduate Medical Education, European Health Centre, Otwock, Poland
References
  • Heit JA, Silverstein MD, Mohr DN et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000; 160(6): 809-815.
  • Thodiyil PA, Kakkar AK. Variation in relative risk of venous thromboembolism in different cancers. Thromb Haemost 2002; 87(6): 1076-1077.
  • Gussoni G, Frasson S, La Regina M et al. Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry. Thromb Res 2013; 131(1): 24-30.
  • Prandoni P, Lensing AW, Piccioli A et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100(10): 3484-3488.
  • Konstantinides SV, Torbicki A, Agnelli G et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014; 35(43): 3033-3069.
  • Lee AY, Levine MN, Baker RI et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349(2): 146-153.
  • Meyer G, Marjanovic Z, Valcke J et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; 162(15): 1729-1735.
  • Akl EA, Labedi N, Barba M et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2011; (6): CD006650.
  • Kakkar AK, Williamson RC. Prevention of venous thromboembolism in cancer patients. Semin Thromb Hemost 1999; 25(2): 239-243.
  • Kearon C, Akl EA, Comerota AJ et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(Suppl. 2): e419S-94S.
  • Mandalà M, Falanga A, Roila F et al. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 2011; 22(Suppl. 6): vi85-92.
  • Akl EA, Labedi N, Terrenato I et al. Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer. Cochrane Database Syst Rev 2011; (11): CD009447.
  • Myojo M, Takahashi M, Tanaka T et al. Midterm Follow-up After Retrievable Inferior Vena Cava Filter Placement in Venous Thromboembolism Patients With or Without Malignancy. Clin Cardiol 2015 [doi: 10.1002/clc.22377].
  • Salati U, Govender P, Torreggiani W et al. Internal jugular and common femoral venous access for the removal of a long-term embedded vena cava filter. Diagn Interv Radiol 2014; 20(4): 341-344.
  • Decousus H, Leizorovicz A, Parent F et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d’Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med 1998; 338(7): 409-415.
  • PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d’Embolie Pulmonaire par Interruption Cave) randomized study. Circulation 2005; 112(3): 416-422.
  • Barginear MF, Lesser M, Akerman ML et al. Need for inferior vena cava filters in cancer patients: a surrogate marker for poor outcome. Clin Appl Thromb Hemost 2009; 15(3): 263-269.
  • Barginear MF, Gralla RJ, Bradley TP et al. Investigating the benefit of adding a vena cava filter to anticoagulation with fondaparinux sodium in patients with cancer and venous thromboembolism in a prospective randomized clinical trial. Support Care Cancer 2012; 20(11): 2865-2872.
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-06691f63-c217-4cc8-b766-f161df4a8e21
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.